Full text

Turn on search term navigation

© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Phage therapy is now reconsidered with interest in the treatment of bacterial infections. A major piece of information for this application is the definition of the molecular targets exploited by phages to infect bacteria. Here, the genetic basis of resistance to the lytic phage φBO1E by its susceptible host Klebsiella pneumoniae KKBO-1 has been investigated. KKBO-1 phage-resistant mutants were obtained by infection at high multiplicity. One mutant, designated BO-FR-1, was selected for subsequent experiments, including virulence assessment in a Galleria mellonella infection model and characterization by whole-genome sequencing. Infection with BO-FR-1 was associated with a significantly lower mortality when compared to that of the parental strain. The BO-FR-1 genome differed from KKBO-1 by a single nonsense mutation into the wbaP gene, which encodes a glycosyltransferase involved in the first step of the biosynthesis of the capsular polysaccharide (CPS). Phage susceptibility was restored when BO-FR-1 was complemented with the constitutive wbaP gene. Our results demonstrated that φBO1E infects KKBO-1 targeting the bacterial CPS. Interestingly, BO-FR-1 was less virulent than the parental strain, suggesting that in the context of the interplay among phage, bacterial pathogen and host, the emergence of phage resistance may be beneficial for the host.

Details

Title
Phage Resistance Is Associated with Decreased Virulence in KPC-Producing Klebsiella pneumoniae of the Clonal Group 258 Clade II Lineage
Author
Lucia Henrici De Angelis 1 ; Poerio, Noemi 2   VIAFID ORCID Logo  ; Vincenzo Di Pilato 3   VIAFID ORCID Logo  ; De Santis, Federica 2 ; Antonelli, Alberto 4   VIAFID ORCID Logo  ; Thaller, Maria Cristina 2   VIAFID ORCID Logo  ; Fraziano, Maurizio 2 ; Rossolini, Gian Maria 4 ; Marco Maria D’Andrea 2   VIAFID ORCID Logo 

 Department of Medical Biotechnologies, University of Siena, Viale Mario Bracci, 16, 53100 Siena, Italy; [email protected] 
 Department of Biology, University of Rome “Tor Vergata”, Via della Ricerca Scientifica snc, 00133 Rome, Italy; [email protected] (N.P.); [email protected] (F.D.S.); [email protected] (M.C.T.); [email protected] (M.F.) 
 Department of Surgical Sciences and Integrated Diagnostics (DISC), University of Genoa, Via Benedetto XV, 6, 16126 Genoa, Italy; [email protected] 
 Department of Experimental and Clinical Medicine, University of Florence, Largo Brambilla, 3, 50121 Florence, Italy; [email protected] (A.A.); [email protected] (G.M.R.); Microbiology and Virology Unit, Florence Careggi University Hospital, Largo Brambilla, 3, 50121 Florence, Italy 
First page
762
Publication year
2021
Publication date
2021
Publisher
MDPI AG
e-ISSN
20762607
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2530180747
Copyright
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.